

We thank the reviewers for high evaluation of this review article. The requested changes were made and marked in red.

1. *There is an imbalance between reporting of pathophysiological changes induced by coinfection and the clinical course and treatment, for which a rather telegraphic approach is maintained.*

**Response:** We added more details about the outcomes and treatment of coinfections.

2. *In particular, one would expect a more detailed reporting of the time to increase stages of fibrosis in studies with serial liver biopsies, if any, or the progression of liver stiffness by non-invasive means in HIV monoinfected compared to HCV and/or HBV coinfecting HIV patients.*

**Response:** We added more details about fibrosis development and liver stiffness, cirrhosis/decompensated cirrhosis and treatment with DAA.

3. *A more practical approach is needed in the section of treatment. Different treatment schedules have been used and reported for coinfection. Not all of them have equal weight. The reader needs a better guidance.*

**Response:** In this review, we provided a general information about the importance of anti-viral treatment of co-infections and mainly focused the factors with a negative impact on outcomes of DAA treatment. We had no intend to evaluate all DAA treatment regimens in details, which is the subject of a special review. However, we included some details requested by the Reviewer 3.to this version as well.